Navigation Links
Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Date:6/2/2009

NEW YORK, June 2 /PRNewswire/ -- Cynvec LLC, a privately held biotechnology company focused on developing novel cancer therapies that harness the apoptotic ability of the sindbis viral vector, today announced that Frank Stonebanks, President and Chief Executive Officer, will make a presentation titled "Cynvec: Breakthrough Oncolytic Viral Vector Therapy with Sindbis" at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry. Mr. Stonebanks' presentation will take place on Wednesday, June 3, 2009 at 10:00 a.m. local time, in Shanghai China. Additional information about the conference can be found at: www.bio-forum.com.

About Cynvec LLC

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets the over expressed laminin receptor on the surface of many solid tumors without affecting normal cells. Under an exclusive worldwide license from the NYU School of Medicine, Cynvec is developing its lead product, CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and pancreatic cancer as both a single agent and in combination with licensed chemotherapies. Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real time cancer diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in the third quarter of 2009. The sindbis vector has demonstrated in vivo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found at www.cynvec.com.


'/>"/>
SOURCE Cynvec LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cynvec to Present at New York Biotechnology Association 18th Annual Meeting
2. Cynvec to Present at the BIO National Venture Conference
3. Cynvec LLC(SM) to Present at the Cowen and Company 29th Annual Health Care Conference
4. Cynvec LLC(SM) to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
5. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
6. ViroPharma to Present at Two June Healthcare Conferences
7. Cynosure Announces Presentations at Upcoming Investor Conferences
8. BioMarin to Present at the Goldman Sachs Healthcare Conference
9. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
10. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... , ... September 12, 2017 , ... ... and highly scalable cloud-based platform for ambulatory patient monitoring and clinical trial support, ... Advance Clinical Trials conference in Boston. , Launched in 2005, PhysIQ leverages ...
(Date:9/12/2017)... ... September 12, 2017 , ... ... ) has announced the release of their latest product LabCODE™, a novel ... requirements. LabCODE™ offers pre-built capabilities for Biobanking, Pharmacokinetics, Pharmacogenetics, Next Generation ...
(Date:9/12/2017)... ... September 12, 2017 , ... Soybean researchers seeking funding from ... "pre-proposal” by October 15, prior to completing a full grant application. , “The ... our priorities, and to encourage researchers to further develop ones that might need ...
(Date:9/12/2017)... ... 2017 , ... VetStem Biopharma, Inc. , announced that a major new ... license to that patent. This patent covers methods for isolating stem ... stem cell with matrix materials, and incorporating the stem cells in an implant. ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
Breaking Biology News(10 mins):